Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/11/2024 | $6.00 | Buy | BTIG Research |
| 10/3/2023 | $10.00 | Overweight | CapitalOne |
| 7/6/2023 | $12.00 | Outperform | Evercore ISI |
| 5/31/2023 | $0.60 → $7.00 | Hold → Buy | Jefferies |
| 5/24/2023 | $10.00 | Buy | H.C. Wainwright |
| 4/14/2023 | $10.00 | Outperform | Robert W. Baird |
Carisma notified Novartis Pharmaceuticals of its termination of the Manufacturing and Supply Agreement, dated March 1, 2023, relating to the manufacture of the first product candidate to enter clinical development, CT-0508. The termination is effective July 31, 2024. Pursuant to the Company’s revised operating plan, the Company determined to focus its ex vivo oncology clinical development efforts on its follow-on product candidate CT-0525 and has suspended enrollment of new patients in its Phase 1 clinical trial for CT-0508. As a result of the termination of the Manufacturing Agreement, the Company will incur a termination fee equal to $4.0 million, which is expected to be paid in the thir
Carisma Therapeutics Inc. (NASDAQ:CARM) shares are trading higher on Friday following the company’s announcement of a significant development in its collaboration with Moderna. What To Know: Carisma has nominated its first in vivo CAR-M development candidate targeting Glypican-3 (GPC3) for the treatment of solid tumors, including hepatocellular carcinoma (HCC). This milestone has triggered a $2 million payment to Carisma from Moderna. The development candidate leverages Carisma’s expertise in engineering chimeric antigen receptor monocytes and macrophages (CAR-M) with Moderna’s mRNA and lipid nanoparticle platform. This collaboration aims to create novel in vivo cell therapies for onco
PTGX: 11% | Protagonist Therapeutics To Join S&P SmallCap 600, Effective Prior To Opening Of Trading On July 3 DJT: 16% | Trump Media & Technology Group shares are trading higher following Thursday's presidential debate. CARM: 95% | Carisma Therapeutics shares are trading higher after the company announced the nomination of the first in vivo CAR-M development candidate for hepatocellular carcinoma under collaboration with Moderna.
SC 13D/A - Carisma Therapeutics Inc. (0001485003) (Subject)
SC 13G - Carisma Therapeutics Inc. (0001485003) (Subject)
SC 13D/A - Carisma Therapeutics Inc. (0001485003) (Subject)
Appointment of Sohanya Cheng Resignation of Michael Torok PHILADELPHIA, Oct. 30, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (NASDAQ:CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced the appointment of Sohanya Cheng, MBA to the Company's Board of Directors, effective October 31, 2024. Additionally, Michael Torok has informed the Board of his intention to step down as a member, effective October 31, 2024, due to other professional commitments. "It's a pleasure to we
PHILADELPHIA, Oct. 4, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (NASDAQ:CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced its upcoming poster presentations at the Society for Immunotherapy of Cancer (SITC), taking place in Houston, Texas, November 6 -10, 2024. Details on the poster presentations at SITC 2024 are below: Title: Pre-clinical efficacy of a novel anti-GPC3 in vivo CAR-M for hepatocellular carcinoma Publication Number: 329Session Date & Time: Friday, N
Building on successful pre-clinical in vivo CAR-M data in oncology, the companies will develop in vivo CAR-M for autoimmune diseases Moderna nominated two autoimmune disease targets under the collaboration Carisma is eligible to receive milestones and royalty payments PHILADELPHIA, Sept. 10, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (NASDAQ:CARM) ("Carisma" or the "Company"), a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced the expansion of its in vivo chimeric antigen receptor macrophage and monocyte (together, "CAR-M") collaboration with Moderna, Inc. (NASDAQ:MRNA) to include the nomination of two targets for
BTIG Research initiated coverage of Carisma Therapeutics with a rating of Buy and set a new price target of $6.00
CapitalOne initiated coverage of Carisma Therapeutics with a rating of Overweight and set a new price target of $10.00
Evercore ISI initiated coverage of Carisma Therapeutics with a rating of Outperform and set a new price target of $12.00
8-K - Carisma Therapeutics Inc. (0001485003) (Filer)
8-K - Carisma Therapeutics Inc. (0001485003) (Filer)
10-Q - Carisma Therapeutics Inc. (0001485003) (Filer)
4 - Carisma Therapeutics Inc. (0001485003) (Issuer)
3 - Carisma Therapeutics Inc. (0001485003) (Issuer)
4 - Carisma Therapeutics Inc. (0001485003) (Issuer)
Appointment of Sohanya Cheng Resignation of Michael Torok PHILADELPHIA, Oct. 30, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (NASDAQ:CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced the appointment of Sohanya Cheng, MBA to the Company's Board of Directors, effective October 31, 2024. Additionally, Michael Torok has informed the Board of his intention to step down as a member, effective October 31, 2024, due to other professional commitments. "It's a pleasure to we
Initial data for CT-0525, lead product candidate for anti-HER2 program, expected by year-end 2024 Nomination of a development candidate for liver fibrosis program expected in the first quarter of 2025 Nominated first in vivo CAR-M development candidate targeting Glypican-3 to treat hepatocellular carcinoma under the Moderna Collaboration in the second quarter of 2024 Cash and cash equivalents of $40.4 million and $2.0 million received in July under the Moderna Collaboration expected to fund the Company into the third quarter of 2025 PHILADELPHIA, Aug. 8, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (NASDAQ:CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focus
Company appoints renowned key opinion leaders in liver fibrosis, Scott Friedman, MD, and Ira Tabas, MD, PhD PHILADELPHIA, Aug. 6, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (NASDAQ:CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced the appointment of Dr. Scott Friedman and Dr. Ira Tabas to its Scientific Advisory Board (SAB). Dr. Friedman and Dr. Tabas bring extensive expertise and pioneering contributions in liver fibrosis, which will be instrumental as Carisma continues its program to develop transformative treatments for patients.